SYDNEY, Australia and SAN DIEGO, Feb. 25, 2011 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), which is developing a novel bioresorbable slide and lock drug-eluting coronary stent, called ReZolve™, is pleased to announce that Jeffrey A. Anderson has joined the company’s executive team as Vice President of Clinical and Regulatory Affairs.
